SCHEMBL30814201

SCHEMBL30814201

CN(C)CCCOCCCc1nc2c(o1)-c1ccccc1Sc1ccccc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.37
CHRM2 P08172 4/20 0.37
HTR1A P08908 4/20 0.37
ADRA2A P08913 4/20 0.37
CHRM1 P11229 4/20 0.37
DRD2 P14416 4/20 0.37
DRD1 P21728 4/20 0.37
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 4/20 0.37
ADRA1A P35348 4/20 0.37
HRH1 P35367 4/20 0.37
OPRM1 P35372 4/20 0.37
DRD3 P35462 4/20 0.37
KCNH2 Q12809 4/20 0.37
CYP1A2 P05177 3/20 0.37
KDM1A O60341 3/20 0.37
CYP2C19 P33261 3/20 0.37
CHRM4 P08173 3/20 0.37
ADRA2B P18089 3/20 0.37
ADRA2C P18825 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289739 1.00 CYP2D6 (0.37) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL5181025 0.96 BCHE (0.36) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL5182835 0.90 CYP2D6 (0.38) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL2290421 0.83 NR4A2 (0.38) HRH3NR4A2NR4A1NR4A3RXRA
SCHEMBL5182945 0.83 BCHE (0.38) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL2293404 0.81 LMNA (0.45) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL30814239 0.81 LMNA (0.45) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL5181405 0.81 LMNA (0.45) CYP2D6CHRM2HTR1AADRA2ACHRM1
SCHEMBL5182953 0.79 NR4A2 (0.38) ADRB2ALDH1A1NR4A2NR4A1NR4A3
SCHEMBL2290286 0.77 RXRA (0.40) CHRM2CHRM1DRD2ADRA1AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed